Date: 2012-02-07
Type of information: R&D agreement
Compound: diagnostic arrays relating to the partner’s oncology pipeline
Company: Prometheus Laboratories (USA - part of Nestlé Health Sciences (Switzerland) - unnamed leading worldwide pharmaceutical company
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: Prometheus’ proprietary oncology diagnostic platform has the ability to measure the expression and activation of specific cancer pathways with high levels of sensitivity and specificity via tissue or blood sample. This technology has the potential to be used not only in the development process to select and evaluate the efficacy of drugs but also in the clinical setting to enable real-time molecular profiling, monitor drug effectiveness and direct the use of a growing number of targeted therapies.
Disease:
Details: Prometheus Laboratories has announced the execution of a research and collaboration agreement with an unnamed leading worldwide pharmaceutical company. The collaboration will use Prometheus’ proprietary oncology diagnostic platform (CEER) to develop diagnostic arrays relating to the partner’s oncology pipeline. The CEER arrays may ultimately be used in clinical trials for patient selection and may potentially accelerate the development of novel oncology therapeutic products.
Financial terms:
Latest news:
